Ligand Pharmaceuticals | LGND - Sales Revenues

Stock Price
207.78
Daily Change
-0.11 -0.05%
Monthly
-10.35%
Yearly
98.04%
Q2 Forecast
208.92

Ligand Pharmaceuticals reported $51.72M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Agenus USD 34.2M 3.97M Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 73.74M 190.29M Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Enviri Corporation USD 555M 19.81M Dec/2025
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 305.96M 42.16M Mar/2026
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.29B 110M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 139.07M 1.53M Mar/2026